uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4][5]. Group 1: Lawsuit Details - The lawsuit was filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [2][7]. - The deadline for investors to seek lead plaintiff status is April 13, 2026 [3][9]. - The case is titled Scocco v. uniQure N.V., et al., and is being heard in the United States District Court for the Southern District of New York [2]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [4][5]. - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that uniQure downplayed the likelihood of needing to delay its BLA timeline due to additional studies [5][6]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II studies would be adequate for BLA submission, leading to a significant drop in share price [6][8]. Group 3: Impact on Share Price - Following the disclosure on November 3, 2025, uniQure's share price fell by $33.40, or over 49%, from $67.69 to $34.29 per share [8].